Merck's earnings call revealed lowered full-year revenue guidance due to patent expirations and currency headwinds, despite maintaining EPS guidance through cost management. While strong performance in key products and a commitment to R&D are positive signs, near-term concerns over declining sales may weigh on investor sentiment. As a result, the stock may experience a slight negative impact in the short term.

[-1]